Paper37213670
Synergistic Effect of Metformin and Lansoprazole Against Gastric Cancer through Growth Inhibition.
Kao HW and 2 others. Int J Med Sci, 2023. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Synergistic Effect of Metformin and Lansoprazole Against Gastric Cancer through Growth Inhibition. Papers, record 37213670. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37213670
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Synergistic Effect of Metformin and Lansoprazole Against Gastric Cancer through Growth Inhibition.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Metformin | Major topic |
| Stomach Neoplasms | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Animals | |
| Humans | |
| Lansoprazole | |
| Proton Pump Inhibitors |
Source PubMed
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18006801 | Targeting vacuolar H+-ATPases as a new strategy against cancer. | Cancer Res | 2007 | https://conductscience.org/library/papers/18006801 | PubMed |
| 2 | 28388576 | Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase. | Oncotarget | 2017 | https://conductscience.org/library/papers/28388576 | PubMed |
| 3 | 21694841 | An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. | Clin Exp Gastroenterol | 2010 | https://conductscience.org/library/papers/21694841 | PubMed |
| 4 | 23151022 | In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. | BMC Cancer | 2012 | https://conductscience.org/library/papers/23151022 | PubMed |
| 5 | 27762303 | AKT/GSK3β signaling pathway is critically involved in human pluripotent stem cell survival. | Sci Rep | 2016 | https://conductscience.org/library/papers/27762303 | PubMed |
| 6 | 28126011 | Metformin targets multiple signaling pathways in cancer. | Chin J Cancer | 2017 | https://conductscience.org/library/papers/28126011 | PubMed |
| 7 | 24820971 | S100A8 contributes to drug resistance by promoting autophagy in leukemia cells. | PLoS One | 2014 | https://conductscience.org/library/papers/24820971 | PubMed |
| 8 | 18228389 | Determining cell cycle stages by flow cytometry. | Curr Protoc Cell Biol | 2001 | https://conductscience.org/library/papers/18228389 | PubMed |
| 9 | 21415163 | Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. | Cancer Res | 2011 | https://conductscience.org/library/papers/21415163 | PubMed |
| 10 | 24802401 | Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. | Biochem Biophys Res Commun | 2014 | https://conductscience.org/library/papers/24802401 | PubMed |
| 11 | 21226640 | Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. | Expert Opin Pharmacother | 2011 | https://conductscience.org/library/papers/21226640 | PubMed |
| 12 | 26351208 | Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells. | Oncol Res | 2014 | https://conductscience.org/library/papers/26351208 | PubMed |
| 13 | 20108024 | Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. | Cancer Metastasis Rev | 2010 | https://conductscience.org/library/papers/20108024 | PubMed |
| 14 | 32246720 | SynergyFinder 2.0: visual analytics of multi-drug combination synergies. | Nucleic Acids Res | 2020 | https://conductscience.org/library/papers/32246720 | PubMed |
| 15 | 32214849 | Anticancer Effects of Antihypertensive L-Type Calcium Channel Blockers on Chemoresistant Lung Cancer Cells via Autophagy and Apoptosis. | Cancer Manag Res | 2020 | https://conductscience.org/library/papers/32214849 | PubMed |
| 16 | 21705069 | National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. | Lancet | 2011 | https://conductscience.org/library/papers/21705069 | PubMed |
| 17 | 33959611 | Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/33959611 | PubMed |
| 18 | 18212742 | The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. | Oncogene | 2008 | https://conductscience.org/library/papers/18212742 | PubMed |
| 19 | 24963109 | Metformin and cancer: mounting evidence against an association. | Diabetes Care | 2014 | https://conductscience.org/library/papers/24963109 | PubMed |
| 20 | 24482380 | V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. | Mol Cancer Ther | 2014 | https://conductscience.org/library/papers/24482380 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42712908 | Repurposing of lansoprazole and nitazoxanide as NR2F2 inhibitors in the gastric cancer cell line GCIY: computational insights and siRNA-mediated in vitro tests. | Front Chem | 2026 | https://conductscience.org/library/papers/42712908 | PubMed |
| 41882204 | Synergistic induction of apoptosis by the epigenetic modulator decitabine and metformin in gastric cancer cells highlights the potential for combination therapy. | Sci Rep | 2026 | https://conductscience.org/library/papers/41882204 | PubMed |
| 40207763 | Metformin and its Nanoformulations in Cancer Prevention and Therapy. | Curr Pharm Des | 2025 | https://conductscience.org/library/papers/40207763 | PubMed |
| 38192437 | Antibacterial and Immunoregulatory Effects of Metformin against Helicobacter pylori Infection in Rat Model. | Biomed Res Int | 2023 | https://conductscience.org/library/papers/38192437 | PubMed |
Genes17
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37213670
GET https://conductscience.org/api/papers/v1/37213670/references?page=2